In pre-clinical studies, EZH2 is found to be overexpressed in docetaxel-resistant prostate cancers cells [110], cisplatin-resistant breast cancer cells [111] and 5-FU resistant gastric cancer cells [112]. Here, EZH2 is linked to Familial prostate cancer.